NCT04752059: Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases

NCT04752059
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have had prior exposure to trastuzumab (Herceptin), pertuzumab (Perjeta), and/or T-DM1 (Kadcyla)
Exclusions: Patients with an indication of leptomeningeal disease; Patients requiring immediate local treatment
https://ClinicalTrials.gov/show/NCT04752059

Comments are closed.

Up ↑